2016

/
/
Page 2
The Epilepsy Foundation: Knowledge about Epilepsy and Risk Factors Survey

The Epilepsy Foundation is constantly enhancing epilepsy.com. To help, they are asking users for a better understanding of what they know about the impact of…

The Epilepsy Foundation SUDEP Institute will be awarding more than $1 million to address Sudden Unexpected Death in Epilepsy (SUDEP)

The Epilepsy Foundation SUDEP Institute will be awarding more than $1 million for a series of four prize challenge competitions working to address Sudden Unexpected…

UMDF Great Lakes Regional Mitochondrial Medicine Symposium

Clinical/Medical Sessions (CME) Friday, May 20, 2016 Patient/Family Sessions (non CME) Saturday, May 21, 2016 To view schedule and speakers – visit www.umdf.org/GreatLakesClinicalAgenda. Complete symposium…

May is Stroke Awareness Month: “I didn’t know a child could have a stroke!”

When people think of a stroke, a child is not the first image that comes to mind. The International Alliance for Pediatric Stroke aims to…

Eisai Announces FDA Approval of FYCOMPA® (perampanel) Oral Suspension for Adjunctive Therapy in the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures

New Formulation Expands Treatment Options for Epilepsy Patients with POS and PGTC Seizures Woodcliff Lake, NJ, May 2, 2016 – Eisai Inc. today announced that…

Eisai Launches Latest Book in Comic Book Series:  “Medikidz Explain Playing Sports With Epilepsy”

Living with epilepsy can be challenging, and even scary at times, but it doesn’t have to stop you from pursuing your dreams. With the help…

CURE: NOW ACCEPTING 2017 Seminar Series Applications!

Host a 2017 CURE Seminar At Your Institution CURE is now accepting applications for the 2017 Frontiers in Research Seminar Series! Approximately 10 seminars will be…

CURE Travel Awards

CURE is Proud to Sponsor the Gordon Research Seminar and Gordon Research Conference on Mechanisms of Epilepsy & Neuronal Synchronization GRS August 20-21, 2016 | GRC August 21-26,…

Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex

– Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients(1) –…

CURE 2016 Cycle 2 Funding Opportunities: Now Accepting Grant Applications

CURE is now accepting LOIs for second 2016 grant cycle. Innovator Award – $50,000 USD paid over 1 year Taking Flight Award – $100,000 USD…

Rare Disease are Not so Rare in Neurology

  Rare diseases are not so rare in neurology, so Neurology Reviews presents the 2nd annual Rare Neurological Disease Special Report, which includes a compendium…

Enroll Now!  CURE’s Epilepsy Genetics Initiative

Our partners at CURE are proud to report that enrollment in the Epilepsy Genetics Initiative (EGI) database continues to grow, with 53 individual epilepsy patients and…

OPENING SOON CURE 2016 Cycle 2 Funding Opportunities

OPENING SOON CURE 2016 Cycle 2 Funding Opportunities CURE will soon be accepting LOIs for our second 2016 grant cycle. Innovator Award – $50,000 USD…

  • 1
  • 2

Start typing and press Enter to search

Shopping Cart